Welcome to our dedicated page for Achieve Life Sciences news (Ticker: ACHV), a resource for investors and traders seeking the latest updates and insights on Achieve Life Sciences stock.
Achieve Life Sciences reports company news around the development and potential commercialization of cytisinicline, an investigational treatment for nicotine dependence. Cytisinicline is a plant-based alkaloid that binds to nicotinic acetylcholine receptors and is being studied for smoking cessation and e-cigarette cessation; it has not been approved by the FDA for any indication in the United States.
Recurring ACHV updates include financial results, clinical data presentations, regulatory and manufacturing progress, supply-chain arrangements for cytisinicline, capital-structure actions, and governance changes. Company announcements also cover scientific publications, board and executive appointments, and operational steps tied to preparing the cytisinicline program for potential commercial use if regulatory approval is obtained.
Achieve Life Sciences (NASDAQ: ACHV), a clinical-stage pharmaceutical firm, will present at the Emerging Growth Virtual Conference from March 17-19, 2021. CEO John Bencich is invited to lead discussions on their product, cytisinicline, aimed at combating nicotine addiction—a major health crisis linked to millions of deaths globally. Cytisinicline is under development as an investigational treatment for smoking cessation. The conference includes various interactive sessions featuring CEOs and investors.
Achieve Life Sciences, Inc. (NASDAQ:ACHV) announced the immediate appointment of Dr. Bridget Martell and Dr. Cindy Jacobs to its Board of Directors. Dr. Martell is recognized for her extensive clinical development expertise, while Dr. Jacobs continues her role as President and Chief Medical Officer. Both bring significant experience in addiction medicine, which aligns with Achieve's mission to develop cytisinicline for smoking cessation. Cytisinicline targets nicotine addiction, although it has not yet received FDA approval. This strategic leadership move aims to bolster the company’s efforts in addressing global nicotine addiction.
Achieve Life Sciences (ACHV) announced its fourth quarter and year-end 2020 results. The company is advancing the Phase 3 ORCA-2 trial of cytisinicline for smoking cessation, targeting 750 adult smokers across 15 U.S. sites. In 2020, Achieve raised $17.3 million through a public offering, enhancing its financial position with cash reserves of $35.9 million by year-end. However, the company reported a fourth-quarter net loss of $4.7 million. Data from the SRNT Annual Meeting revealed low satisfaction with current cessation treatments, indicating a market need for effective alternatives.
Achieve Life Sciences, Inc. (NASDAQ:ACHV) will announce its fourth quarter and year-end 2020 financial results on March 11, 2021, at 4:30 PM ET. The company is focused on the global development of cytisinicline for smoking cessation and nicotine addiction. Interested parties can access the conference call via the Investor Relations page on the Achieve website or by dialing in. A replay will be available after the call. This marks a significant opportunity for stakeholders to assess the company's financial health and developments in their product pipeline.
Achieve Life Sciences (Nasdaq: ACHV) announced the presentation of three posters at the SRNT Annual Meeting on February 24, 2021. The data highlighted the low satisfaction levels among smokers concerning current cessation treatments and indicated that over 75% of Chantix users do not complete the recommended therapy course. Additionally, 73% of e-cigarette users plan to quit vaping within the next year. Achieve is enrolling participants for the Phase 3 ORCA-2 study of cytisinicline, a potential new treatment for nicotine addiction.
Achieve Life Sciences (NASDAQ: ACHV) will present at the MicroCap Rodeo Winter Wonderland Conference from February 16-19, 2021. CEO John Bencich is scheduled to speak on February 16 at 12:30 p.m. EST. The presentation will be available for live streaming and replay at their investor relations site.
The conference highlights 35 investment opportunities recommended by institutional investors, focusing on companies like Achieve, which is dedicated to resolving nicotine addiction through its product, cytisinicline.
Achieve Life Sciences (NASDAQ:ACHV) will have CEO John Bencich present at the H.C. Wainwright BioConnect Conference from January 11-14, 2021. The presentation will be available via webcast starting January 11 at 6:00 AM EST on the Achieve Investor Relations page. The company focuses on developing cytisinicline, a plant-based treatment for nicotine addiction, which is approved in Central and Eastern Europe and has helped over 20 million users. Smoking remains a leading cause of preventable death worldwide, emphasizing the importance of Achieve’s mission.
Achieve Life Sciences (Nasdaq: ACHV) has successfully closed a public offering of 2,472,500 shares at $7.00 each, raising $17.3 million before expenses. The offering included the underwriter's full over-allotment of 322,500 shares. Proceeds will support the Phase 3 ORCA-2 trial, clinical research, and general corporate needs, extending the company's financial runway into mid-2022. Lake Street Capital Markets was the sole bookrunning manager, and the registration was declared effective by the SEC on December 2, 2020.
Achieve Life Sciences (Nasdaq: ACHV) announced a public offering of 2,150,000 shares at $7.00 each, aiming to raise approximately $15 million. The offering, set to close around December 7, 2020, includes a 30-day option for underwriters to purchase an additional 322,500 shares. Proceeds will fund the Phase 3 ORCA-2 trial and support clinical research and corporate purposes. This offering follows a recent SEC registration, positioning Achieve to enhance its development of cytisinicline, a promising aid for smoking cessation.
Achieve Life Sciences (Nasdaq: ACHV) announced a proposed underwritten public offering of 1,500,000 shares of common stock, along with an option for underwriters to purchase an additional 225,000 shares. The offering, managed by Lake Street Capital Markets LLC with Maxim Group LLC as co-manager, aims to fund the Phase 3 ORCA-2 trial and support clinical research, development, and general corporate purposes. A registration statement has been filed with the SEC, but the completion and terms of the offering remain uncertain due to market conditions.